CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 701-708

  Cui, Fei ^a   Wang, Jian ^a   Chen, Duan ^b   Chen, Yi Jiang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cancer stem cells; CD133; H446; Tumorigenesis

Indexed keywords

CD133 ANTIGEN;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; CELL STRAIN A549; CELL STRAIN CALU 1; CELL STRAIN H157; CELL STRAIN H226; CELL STRAIN H292; CELL STRAIN H446; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; SMALL CELL LUNG CARCINOMA; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551605961     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1115     Document Type: Article

References (28)

1. Boyle P and Levin B: World Cancer Report 2008. Vol. 390, International Agency for Research on Cancer, Lyon, 2008.
2. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A and Genestreti G: Small cell lung cancer. Ann Oncol 17 (Suppl 2): ii5-ii10, 2006.
3. Simon GR and Wagner H: Small cell lung cancer. Chest 123: S259-S271, 2003.
4. Lapidot T, Sirard C, Vormoor J, et al: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
5. - glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015, 2007.
6. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1436-1440, 2007.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
8. Collins AT, Berry PA, Hyde C, Stower MJ and Maitl NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
9. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824, 2006.
10. Dome B, Timar J, Dobos J, et al: Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66: 7341-7347, 2006.
11. Hohenberger P, Nowak K, Rafat N, et al: The level of circulating endothelial progenitor cells is increased in human lung cancer patients and correlates with the progression of the disease. J Clin Oncol 26: 22055, 2008.
12. Meng X, Wang X and Wang Y: More than 45% of A549 and H446 cells are cancer initiating cells: Evidence from cloning and tumorigenic analyses. Oncol Rep 21: 995-1000, 2009.
13. Qiang-gang D, Ming Y, Qin G, Jin Z and Ming-xia Y: Isolation and identification of human lung adenocarcinoma stem cells. Tumor 28: 1-7, 2008 (In Chinese).
14. Bhattacharyya S and Khanduja KL: New hope in the horizon: cancer stems cells. Acta Biochim Biophys Sin (Shanghai) 42: 237-242, 2010.
15. Paguirigan A, Beebe DJ, Liu B and Alexander C: Mammary stem and progenitor cells: tumour precursors? Eur J Cancer 42: 1225-1226, 2006.
16. Mackenzie IC: Stem cell properties and epithelial malignancies. Eur J Cancer 42: 1204-1212, 2006.
17. Haura E: Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination? Med Hypotheses 67: 951-956, 2006.
18. Kim CF, Jackson EL, Woolfenden AE, et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835, 2005.
19. Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997.
20. Hayashi T, Tao H, Jida M, et al: Expression of CD133, a possible marker for cancer stem cells (CSCs), in small cell lung cancer (SCLC) cell lines and non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 27: e22100, 2009.
21. Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001.
22. Frank NY, Margaryan A, Huang Y, et al: ABCB5-mediated doxorubicin transport and chemoresistance human malignant melanoma. Cancer Res 65: 4320-4333, 2005.
23. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
24. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.
25. Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol 214: 3-9, 2008.
26. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
27. + hematopoietic cells from adults: gain and loss of CD34 antigen by undifferentiated cells are closely linked to proliferative status in culture. Stem Cells 22: 556-569, 2004.
28. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.